AIM: To examine the incidence of @entity1722 oncogene amplification in clinically localised @entity263 using in situ hybridisation. METHODS: One hundred and seventeen @entity1 , who had undergone radical prostatectomy, were identified and in situ hybridisation was performed on @entity406 fixed, paraffin wax embedded tissue using the Quantum Appligene probe for @entity1722 . The enzyme peroxidase was used to detect the probe because this enabled a permanent record to be kept. @entity5 in which there were five or more signals in each nucleus in > 20% of the @entity5 cells were considered to have a significantly increased copy number. A serial section from these @entity5 was then hybridised with the chromosome 17 alpha satellite probe. The ratio of the percentage of cells showing an increase in @entity1722 copy number to the number showing polysomy for chromosome 17 was calculated. A ratio above 2 was considered amplified. RESULTS: Biochemical recurrence occurred in 50 (43%) @entity1 and 24 (21%) had clinical recurrence. In situ hybridisation for @entity1722 was accessible in 114 (97%) @entity1 . A significant increase in copy number was present in two @entity1 (1.75 %), but chromosome 17 hybridisation showed that the increase was the result of polysomy rather than true amplification. Both these @entity1 had a Gleason score of 7 and stage T3; they also had recurrent clinical disease with distal metastasis within two and 19 months. CONCLUSIONS: Increased @entity1722 oncogene copy number appears to be rare in clinically localised @entity263 and is related to chromosome 17 polysomy rather than true amplification. As a result, it would not be a useful biomarker for identifying those @entity1 who will have recurrences after radical prostatectomy.

XXXX oncogene amplification in clinically localised @entity263 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic adenocarcinoma', 'prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumours', 'tumours', 'tumour'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin'] @entity1722 :: ('2064', 'Gene') :: ['Her-2/neu']
@entity1722 :: (2064,Gene) :: ['Her-2/neu']
